David P Nadebaum1,2, Natasha Krishnadas1, Aurora Mt Poon1, Victor Kalff2, Meir Lichtenstein3, Victor L Villemagne1,4, Gareth Jones1, Christopher C Rowe1,4. 1. Department of Molecular Imaging and Therapy, Austin Hospital, 145 Studley Road, Heidelberg, Victoria, 3084, Australia. 2. Department of Nuclear Medicine, Alfred Hospital, 55 Commercial Road, Prahran, Victoria, 3004, Australia. 3. Department of Nuclear Medicine, Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria, 3050, Australia. 4. The University of Melbourne, Parkville, Victoria, 3010, Australia.
Abstract
BACKGROUND: Clinical diagnosis of Alzheimer's disease (AD) is only 70% accurate. Reduced cerebral blood flow (CBF) and metabolism in parieto-temporal and posterior cingulate cortex may assist diagnosis. Whilst widely accepted that 18 F-FDG PET has superior accuracy to CBF SPECT for AD, there is very limited head-to-head data from clinically relevant populations and these studies relied on clinical diagnosis as the reference standard. AIM: To directly compare the accuracy of CBF-SPECT and 18 F-FDG PET in patients referred for diagnostic studies in detecting β-amyloid PET confirmed AD. METHODS: 126 patients, 56% with mild cognitive impairment and 44% with dementia, completed both CBF-SPECT and 18 F-FDG PET as part of their diagnostic assessment, and subsequently underwent β-amyloid PET for research purposes. Transaxial slices and Neurostat 3D-SSP analyses of 18 F-FDG PET and CBF-SPECT scans were independently reviewed by five nuclear medicine clinicians blinded to all other data. Operators selected the most likely diagnosis and their diagnostic confidence. Accuracy analysis used final diagnosis incorporating β-amyloid PET as the reference standard. RESULTS: Clinicians reported high diagnostic confidence in 83% of 18 F-FDG PET compared to 67% for CBF-SPECT (p=0.001). All reviewers showed individually higher accuracy using 18 F-FDG PET. Based on majority read, the combined AUROC in diagnosing AD was 0.71 for 18 F-FDG PET and 0.61 for CBF-SPECT (p=0.02). The sensitivity of 18 F-FDG PET and CBF-SPECT was 76% vs 43% (p<0.001), whilst specificity was 74% vs 83% (p=0.45). CONCLUSION: 18 F-FDG PET is superior to CBF-SPECT in detecting Alzheimer's disease amongst patients referred for the assessment of cognitive impairment. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
BACKGROUND: Clinical diagnosis of Alzheimer's disease (AD) is only 70% accurate. Reduced cerebral blood flow (CBF) and metabolism in parieto-temporal and posterior cingulate cortex may assist diagnosis. Whilst widely accepted that 18 F-FDG PET has superior accuracy to CBF SPECT for AD, there is very limited head-to-head data from clinically relevant populations and these studies relied on clinical diagnosis as the reference standard. AIM: To directly compare the accuracy of CBF-SPECT and 18 F-FDG PET in patients referred for diagnostic studies in detecting β-amyloid PET confirmed AD. METHODS: 126 patients, 56% with mild cognitive impairment and 44% with dementia, completed both CBF-SPECT and 18 F-FDG PET as part of their diagnostic assessment, and subsequently underwent β-amyloid PET for research purposes. Transaxial slices and Neurostat 3D-SSP analyses of 18 F-FDG PET and CBF-SPECT scans were independently reviewed by five nuclear medicine clinicians blinded to all other data. Operators selected the most likely diagnosis and their diagnostic confidence. Accuracy analysis used final diagnosis incorporating β-amyloid PET as the reference standard. RESULTS: Clinicians reported high diagnostic confidence in 83% of 18 F-FDG PET compared to 67% for CBF-SPECT (p=0.001). All reviewers showed individually higher accuracy using 18 F-FDG PET. Based on majority read, the combined AUROC in diagnosing AD was 0.71 for 18 F-FDG PET and 0.61 for CBF-SPECT (p=0.02). The sensitivity of 18 F-FDG PET and CBF-SPECT was 76% vs 43% (p<0.001), whilst specificity was 74% vs 83% (p=0.45). CONCLUSION:18 F-FDG PET is superior to CBF-SPECT in detecting Alzheimer's disease amongst patients referred for the assessment of cognitive impairment. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
Authors: Nick Corriveau-Lecavalier; Wentao Li; Vijay K Ramanan; Daniel A Drubach; Gregory S Day; David T Jones Journal: J Neurol Date: 2022-03-01 Impact factor: 6.682
Authors: Nick Corriveau-Lecavalier; Eva C Alden; Nikki H Stricker; Mary M Machulda; David T Jones Journal: Arch Clin Neuropsychol Date: 2022-08-23 Impact factor: 3.448
Authors: Timo Tuovinen; Janne Kananen; Zalan Rajna; Johannes Lieslehto; Vesa Korhonen; Riikka Rytty; Heli Mattila; Niko Huotari; Lauri Raitamaa; Heta Helakari; Ahmed Abou Elseoud; Johanna Krüger; Pierre LeVan; Osmo Tervonen; Juergen Hennig; Anne M Remes; Maiken Nedergaard; Vesa Kiviniemi Journal: Sci Rep Date: 2020-12-09 Impact factor: 4.379